DAAN Biotherapeutics is developing cell therapy and antibody therapy technologies utilizing T-cell receptors (TCRs) to overcome the limitations of existing lung cancer treatments. The company is specifically targeting the treatment of EGFR-mutant lung cancer. Based in South Korea, our company conducts research and development for cancer treatments including cell therapies, antibodies, and small molecule inhibitors in the Asia-Pacific region, as well as around the globe.

DAAN Biotherapeutics is developing a new immune cell therapy against lung cancer that expresses T Cell Receptors (TCR) based on natural killer cells. Currently, most natural killer cell therapeutics are being developed in the form of limited antigen-targeted cell therapeutics through a simple proliferation of natural killer cells isolated from peripheral blood and administration or expression of chimeric antigen receptors. On the other hand, our cell therapy products are natural killer cells expressing TCR that can selectively and effectively target EGFR mutations. By inducing specific killings that target cancer antigens, we are devising an innovative strategy that is completely novel compared to general natural killer cell-based treatments.

Private

Biotech